Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Ewing Sarcoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Sarcoma (608
)
Soft Tissue Sarcoma (395
)
Spindle Cell Sarcoma (93
)
Osteosarcoma (53
)
Leiomyosarcoma (52
)
Fibrosarcoma (33
)
Rhabdomyosarcoma (29
)
Liposarcoma (23
)
Uterine Corpus Leiomyosarcoma (22
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (12
)
Sarcoma (608
)
Soft Tissue Sarcoma (395
)
Spindle Cell Sarcoma (93
)
Osteosarcoma (53
)
Leiomyosarcoma (52
)
Fibrosarcoma (33
)
Rhabdomyosarcoma (29
)
Liposarcoma (23
)
Uterine Corpus Leiomyosarcoma (22
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (12
)
›
Associations
(42)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
IE
Sensitive: A2 - Guideline
IE
Sensitive
:
A2
IE
Sensitive: A2 - Guideline
IE
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
VC
Sensitive: A2 - Guideline
VC
Sensitive
:
A2
VC
Sensitive: A2 - Guideline
VC
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
GT
Sensitive: A2 - Guideline
GT
Sensitive
:
A2
GT
Sensitive: A2 - Guideline
GT
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
melphalan + busulfan
Sensitive: A2 - Guideline
melphalan + busulfan
Sensitive
:
A2
melphalan + busulfan
Sensitive: A2 - Guideline
melphalan + busulfan
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
ifosfamide + cyclophosphamide + etoposide IV + topotecan
Sensitive: A2 - Guideline
ifosfamide + cyclophosphamide + etoposide IV + topotecan
Sensitive
:
A2
ifosfamide + cyclophosphamide + etoposide IV + topotecan
Sensitive: A2 - Guideline
ifosfamide + cyclophosphamide + etoposide IV + topotecan
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
temozolomide + irinotecan
Sensitive: A2 - Guideline
temozolomide + irinotecan
Sensitive
:
A2
temozolomide + irinotecan
Sensitive: A2 - Guideline
temozolomide + irinotecan
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
temozolomide + irinotecan + vincristine
Sensitive: A2 - Guideline
temozolomide + irinotecan + vincristine
Sensitive
:
A2
temozolomide + irinotecan + vincristine
Sensitive: A2 - Guideline
temozolomide + irinotecan + vincristine
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
carboplatin + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
carboplatin + ifosfamide + etoposide IV
Sensitive
:
A2
carboplatin + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
carboplatin + ifosfamide + etoposide IV
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
cabozantinib tablet
Sensitive: A2 - Guideline
cabozantinib tablet
Sensitive
:
A2
cabozantinib tablet
Sensitive: A2 - Guideline
cabozantinib tablet
Sensitive
:
A2
TMB-H
Ewing Sarcoma
TMB-H
Ewing Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
C1
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
C1
MSI-H/dMMR
Ewing Sarcoma
MSI-H/dMMR
Ewing Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
VIDE
Sensitive: A2 - Guideline
VIDE
Sensitive
:
A2
VIDE
Sensitive: A2 - Guideline
VIDE
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
VAIA
Sensitive: A2 - Guideline
VAIA
Sensitive
:
A2
VAIA
Sensitive: A2 - Guideline
VAIA
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
VDC
Sensitive: A2 - Guideline
VDC
Sensitive
:
A2
VDC
Sensitive: A2 - Guideline
VDC
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
lurbinectedin
Sensitive: A2 - Guideline
lurbinectedin
Sensitive
:
A2
lurbinectedin
Sensitive: A2 - Guideline
lurbinectedin
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
SP2577
Sensitive: B - Late Trials
SP2577
Sensitive
:
B
SP2577
Sensitive: B - Late Trials
SP2577
Sensitive
:
B
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
ONCT-216
Sensitive: B - Late Trials
ONCT-216
Sensitive
:
B
ONCT-216
Sensitive: B - Late Trials
ONCT-216
Sensitive
:
B
MGMT promoter methylation
Ewing Sarcoma
MGMT promoter methylation
Ewing Sarcoma
temozolomide + irinotecan
Sensitive: C2 – Inclusion Criteria
temozolomide + irinotecan
Sensitive
:
C2
temozolomide + irinotecan
Sensitive: C2 – Inclusion Criteria
temozolomide + irinotecan
Sensitive
:
C2
IGF1R underexpression
Ewing Sarcoma
IGF1R underexpression
Ewing Sarcoma
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
mTOR inhibitor + IGF-1R inhibitor
Sensitive
:
C3
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
mTOR inhibitor + IGF-1R inhibitor
Sensitive
:
C3
IGF1 elevation
Ewing Sarcoma
IGF1 elevation
Ewing Sarcoma
CP-751,871
Sensitive: C3 – Early Trials
CP-751,871
Sensitive
:
C3
CP-751,871
Sensitive: C3 – Early Trials
CP-751,871
Sensitive
:
C3
PTPRD R995C
Ewing Sarcoma
PTPRD R995C
Ewing Sarcoma
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
mTOR inhibitor + IGF-1R inhibitor
Sensitive
:
C3
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
mTOR inhibitor + IGF-1R inhibitor
Sensitive
:
C3
PTPRD V253I + PTPRD W775stop
Ewing Sarcoma
PTPRD V253I + PTPRD W775stop
Ewing Sarcoma
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
mTOR inhibitor + IGF-1R inhibitor
Sensitive
:
C3
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
mTOR inhibitor + IGF-1R inhibitor
Sensitive
:
C3
PTPRD V253I + PTPRD W775stop
Ewing Sarcoma
PTPRD V253I + PTPRD W775stop
Ewing Sarcoma
IGF-1R inhibitor
Sensitive: C3 – Early Trials
IGF-1R inhibitor
Sensitive
:
C3
IGF-1R inhibitor
Sensitive: C3 – Early Trials
IGF-1R inhibitor
Sensitive
:
C3
SPARC overexpression
Ewing Sarcoma
SPARC overexpression
Ewing Sarcoma
albumin-bound paclitaxel
Sensitive: C3 – Early Trials
albumin-bound paclitaxel
Sensitive
:
C3
albumin-bound paclitaxel
Sensitive: C3 – Early Trials
albumin-bound paclitaxel
Sensitive
:
C3
B4GALNT1 expression
Ewing Sarcoma
B4GALNT1 expression
Ewing Sarcoma
dinutuximab beta
Sensitive: C3 – Early Trials
dinutuximab beta
Sensitive
:
C3
dinutuximab beta
Sensitive: C3 – Early Trials
dinutuximab beta
Sensitive
:
C3
EWSR1-FLI1 fusion
Ewing Sarcoma
EWSR1-FLI1 fusion
Ewing Sarcoma
VDC
Sensitive: C4 – Case Studies
VDC
Sensitive
:
C4
VDC
Sensitive: C4 – Case Studies
VDC
Sensitive
:
C4
FGFR3 amplification + FGFR4 amplification + FLT4 amplification
Ewing Sarcoma
FGFR3 amplification + FGFR4 amplification + FLT4 amplification
Ewing Sarcoma
trametinib + pazopanib
Resistant: C4 – Case Studies
trametinib + pazopanib
Resistant
:
C4
trametinib + pazopanib
Resistant: C4 – Case Studies
trametinib + pazopanib
Resistant
:
C4
CD99 positive + VIM positive
Ewing Sarcoma
CD99 positive + VIM positive
Ewing Sarcoma
OPEC
Sensitive: C4 – Case Studies
OPEC
Sensitive
:
C4
OPEC
Sensitive: C4 – Case Studies
OPEC
Sensitive
:
C4
IGF1R expression
Ewing Sarcoma
IGF1R expression
Ewing Sarcoma
IGF-1R inhibitor
Sensitive: D – Preclinical
IGF-1R inhibitor
Sensitive
:
D
IGF-1R inhibitor
Sensitive: D – Preclinical
IGF-1R inhibitor
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login